Thirty-five healthy, male subjects without brain injury, neuropsychological disorders were included in this study. The majority of the participants in this study were included in a previous study [15 ]. An intravenous bolus injection of 18F-FP-CIT was administered. The emission data were acquired over 90 min with 50 frames of progressively increasing durations (15 s × 8 frames, 30 s × 16 frames, 60 s × 10 frames, 240 s × 10 frames, and 300 s × 6 frames) using the Siemens Biograph 40 Truepoint PET/CT (Siemens Healthcare, Knoxville, Tennessee, USA). The dynamic PET data were collected in the 3-dimensional mode, with 148 slices with image sizes of 256 × 256 and pixel sizes of 1.3364 × 1.3364 mm2. These were reconstructed using iterative method with a Gaussian filter.
Biograph 40 truepoint pet ct
Manufactured by Siemens
Sourced in United States, Germany
The Biograph 40 TruePoint PET/CT is a medical imaging system that combines positron emission tomography (PET) and computed tomography (CT) technologies. It is designed to acquire high-quality images for diagnostic and treatment planning purposes.
Automatically generated - may contain errors
Lab products found in correlation
7 protocols using biograph 40 truepoint pet ct
1
Dynamic PET Imaging of Dopamine Transporter
2
Standardized PET/CT Imaging Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
All patients fasted for at least 6 hours before PET/CT scanning. The plasma glucose level measured before 18F-FDG injection was <150 mg/dL in all patients. 18F-FDG was intravenously administered at a dose of 5.18 MBq/kg (range, 114.3–488.4 MBq); 1 hour after 18F-FDG administration, PET/CT scanning was performed with different systems (Discovery PET/CT 690, 690 Elite, 710; GE Healthcare; Biograph 40 TruePoint PET/CT; Siemens). First, low-dose CT acquisition was performed from the skull base to the upper thigh using the following parameters: 120 kVp, automatic mA, 40 mm collimation, and 3.75 mm thickness for the GE Healthcare machines; 120 kVp, CARE Dose 4D, 28.8 mm collimation, and 5.0 mm thickness for the Siemens machine. A PET scan of the same area was acquired after the CT scan in the 3-dimensional mode with 6 to 7 beds (2 and 2.5 minutes per bed position on the GE Healthcare and Siemens machines, respectively). Images were corrected for attenuation and reconstructed using the 3-dimensional ordered subset expectation maximization (OSEM) method with time-of-flight (TOF) and point-spread-function (PSF) algorithms (192 × 192 matrix, 4 iterations, 18 subsets, 4 mm postsmoothing on GE Healthcare; 168 × 168 matrix, 3 iterations, 21 subsets, 3 mm postsmoothing on Siemens).
3
Comparative Analysis of 68Ga-DOTA-SSA and 18F-FDG PET/CT in Cancer
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
All SSTR PET/CTs were performed on a dedicated hybrid scanner (Biograph 16-slice HiRez LSO PET/CT (Siemens, Erlangen, Germany), Biograph 40 TruePoint PET/CT (Siemens, Erlangen, Germany) or Discovery MI4 PET/CT (GE, Milwaukee, WI, USA)). These cameras were EARL accredited for [18F]FDG and cross-calibrated for gallium-68. However, they are not accredited by the recently launched EARL accreditation programme for gallium-68. The tracer used was initially [68Ga]Ga-DOTATOC (synthesis as described) [34 (link)], with a switch to [68Ga]Ga-DOTATATE from the end of 2012 onwards. If an [18F]FDG PET/CT was performed during diagnostic work-up with a maximum interval of 6 months from the SSTR PET/CT, these data were retrieved for paired analysis. A paired analysis was only done if no therapeutic interventions occurred during the time interval between [18F]FDG and SSTR PET/CT. All images were re-evaluated using MIM software v 7.0 (MIM Software Inc., Cleveland, Ohio, USA) with annotation of the maximum standardized uptake value (SUVmax) in the primary tumour, in all hilar and mediastinal lymph node stations that were pathologically evaluated and in each metastatic organ (distant lymph nodes, liver, bone, etc.). In patients with multiple metastatic lesions in one organ, the SUVmax of the most [68Ga]Ga-DOTA-SSA- or [18F]FDG-avid lesion was noted.
4
Quantifying Lung Inflammation with 18F-FDG PET/CT
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
18 F-fluorodeoxyglucose positron emission tomography-computed tomography ( 18 F-FDG PET/CT) was used to assess active lung inflammation at baseline and week 4 in a consecutively enrolled subset of a planned study with 48 participants, as previously described [16] . In brief, scans were done using an integrated 40-detector PET/CT scanner (Biograph 40 Truepoint PET/CT; Siemens Medical, IL, Hoffman Estates). We applied a threshold of >1 standardized uptake value (SUV) within the segmented lung area. The total FDG signal for this 3-dimensional area was multiplied by the region's volume, and the aggregate activity in both lungs is referred to as the total glycolytic activity (TGA).
5
FDG-PET Imaging of Metabolic Activity
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
FDG‐PET images were acquired using a Siemens Biograph 40 Truepoint PET‐CT 30 minutes after an intravenous bolus administration of 250 MBq 18F‐FDG. The Siemens scanner software was used for iterative reconstruction (OSEM2D, 6 iterations, 16 subsets) with a tissue attenuation correction based on the CT scan obtained immediately before the FDG‐PET scan. All participants were asked to arrive in a fasting state (at least 4 hours before FDG administration). Blood glucose was measured and was <180 mg/dL (10 mM/L) in all participants.
6
Melanoma PET/CT Imaging Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Patients selected for inclusion received whole-body 18F-FDG PET/CT from January 10, 2007, to January 1, 2018, with a diagnosis of malignant melanoma. These patients were identified by running a query of the PACS system. All 18F-FDG PET/CT images were acquired using Siemens Biograph 40 TruePoint PET/CT (Knoxville, TN). The PET component was composed of lutetium oxyortho-silicate (LSO) crystals. The CT component had 40 slice multidetector-row with 70 cm transverse field of view. The acquisition parameters consist of 120 kV, 60 mAs, 0.5 s rotation time, 5 mm slice thickness, and 0.8 pitch.
The image acquisition involved two fields, one from the vertex of the skull to pelvis with 3–4 min per bed position (range for incubation period 56–102 min, mean 113 min) and second from the pelvis to toes with 1–2 min per bed position (range for incubation period 90–207 min, and mean 121 min). The time interval between the two fields of the study ranged from 29 to 56 min (mean 37 min). The patient’s arms were positioned down during acquisition.
The image acquisition involved two fields, one from the vertex of the skull to pelvis with 3–4 min per bed position (range for incubation period 56–102 min, mean 113 min) and second from the pelvis to toes with 1–2 min per bed position (range for incubation period 90–207 min, and mean 121 min). The time interval between the two fields of the study ranged from 29 to 56 min (mean 37 min). The patient’s arms were positioned down during acquisition.
7
FDG-PET Imaging Procedure for Parkinson's Disease
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
FDG-PET was acquired over 10 min at Newcastle University using a Siemens Biograph 40 Truepoint PET-CT starting 30 min after intravenous administration of 250 MBq F-18 FDG. Siemens software was used for iterative reconstruction (OSEM2D 6 iterations, 16 subsets) with model-based scatter correction and attenuation correction based on the CT scan data obtained immediately before the FDG-PET scan. Participants were asked to fast for 4 hours preinjection and blood glucose was tested to ensure it was <180 mg/dL. Participants were injected in quiet surroundings with minimal distractions and with their eyes open. The patients with PD were scanned in an 'on' state, after taking their usual dopaminergic medication.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!